|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 15
|
Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term
|
|
Mar 4
|
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position
|
|
Feb 14
|
Bristol Myers is Tapping US High-Grade Bond Market to Fund M&A
|
|
Jan 12
|
Chief Medical Officer Stephen Brannan Sells 15,000 Shares of Karuna Therapeutics Inc
|
|
Jan 9
|
JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform
|
|
Dec 28
|
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
|
|
Dec 27
|
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
|
|
Dec 27
|
Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca
|
|
Dec 26
|
Bristol Myers buying RayzeBio, FedEx buyback: Trending tickers
|
|
Dec 26
|
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
|
|
Dec 26
|
Why Is RayzeBio (RYZB) Stock Up 100% Today?
|
|
Dec 26
|
Karuna downgraded, Arm target raised: Wall Street's top analyst calls
|
|
Dec 26
|
3 Charts For Investors to Watch Tuesday: Bitcoin, Oil, XBI ETF
|
|
Dec 22
|
Stock Market Closes Mixed But Indexes Post Weekly Gains; The Dow Got Coal Today
|
|
Dec 22
|
Bristol's $14 Billion Takeover Of Karuna Pulled A Bevy Of Stocks Higher
|
|
Dec 22
|
Rocket Lab, Coinbase, Bristol Myers-Karuna deal: Trending tickers
|
|
Dec 22
|
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
|
|
Dec 22
|
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
|
|
Dec 22
|
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
|